Oregon Therapeutics & Lantern Pharma Collaborate To Optimize Cancer Drug
Lantern Pharma Inc. (NASDAQ: LTRN) partners with Oregon Therapeutics to advance the development of XCE853, a pioneering PDI inhibitor, across various cancer types. Leveraging Lantern's RADR® AI platform, the collaboration aims to identify biomarkers and efficacy signatures, crucial for precision development and patient selection. This strategic alliance seeks to address the complexities associated with PDI inhibitors, offering a promising pathway to enhance cancer treatment strategies.
Oregon Therapeutics' CEO, Marc-Henry PITTY, underscores XCE853's preclinical efficacy and the potential for targeted development across multiple cancers. Through comprehensive molecular analysis powered by RADR®, the collaboration intends to uncover new insights into XCE853's therapeutic potential and its application in additional cancer indications. Panna Sharma, CEO of Lantern Pharma, emphasizes RADR®'s role in navigating the complexities of drug development, enabling informed decisions crucial for advancing XCE853 towards clinical success. With equal IP co-ownership, this collaboration marks a significant step towards pioneering AI-driven solutions in cancer therapeutics.

Comments
Post a Comment